Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer Treatment

Inclusion Criteria:

* Patient who has been clearly informed of the study and has agreed, with sufficient time for reflection, to participate by signing the study informed consent form.
* Male aged ≥ 50 years,
* PSA ≤ 15 ng/mL
* diagnosis of localized prostate cancer (stage T1 or T2) with a Gleason score of ≤ 7
* Focal, hemiablation or ablation HIFU treatment validated in Multidisciplinary Concerted Meeting
* Patient enrolled in Medicare or equivalent plan.
* Interpretable preoperative multiparametric MRI performed within 180 days prior to surgery

Exclusion Criteria:

* an ASA score \>3
* brachytherapy for prostate cancer
* Person of full age protected by law (person under guardianship or curatorship).
* Contraindication to HIFU treatment as defined in the Focal One instructions for use : - Multiple intraprostatic calcifications inducing, on ultrasound, a shadow cone in the prostate preventing the penetration of ultrasound and therefore the realization of the treatment.
* Presence of permanent radioactive implants in the rectal wall.
* Presence of an implant (stent, catheter) located less than 1 cm from the treatment area.
* Fistula of the urinary tract or rectum.
* Anal or rectal fibrosis, anal or rectal stenosis or other abnormalities making insertion of the Focal One® catheter difficult.
* Anatomical abnormality of the rectum or rectal mucosa.
* Patient with an artificial sphincter, penile prosthesis or intraprostatic implant, such as a stent.
* History of inflammatory bowel disease.
* Current urogenital infection (infection should be treated prior to HIFU treatment).
* Patient allergic to latex with known severe reactionsCounter-indications to anesthesia